Tissue engineering heart valves: Valve leaflet replacement study in a lamb model

doi:10.1016/0003-4975(95)00733-4

The Annals of Thoracic Surgery

Volume 60, Supplement 3, December 1995, Pages S513-S516

https://doi.org/10.1016/0003-4975(95)00733-4 Get rights and content

Background

Valve replacements using either bioprosthetic or mechanical valves have the disadvantage that these structures are unable to grow, repair, or remodel and are both thrombogenic and susceptible to infection. These characteristics have significantly limited their durability and longevity. In an attempt to begin to overcome these shortcomings, we have tested the feasibility of constructing heart valve leaflets in lambs by seeding a synthetic polyglycolic acid fiber matrix in vitro with fibroblasts and endothelial cells.

Methods

Mixed cell populations of endothelial cells and fibroblasts were isolated from explanted ovine arteries. Endothelial cells were selectively labeled with an acetylated low-density lipoprotein marker and separated from the fibroblasts using a fluorescent activated cell sorter. A synthetic biodegradable scaffold constructed from polyglycolic acid fibers was seeded with fibroblasts, which grew to form a tissue-like sheet. This tissue was subsequently seeded with endothelial cells, which formed a cellular monolayer coating around the leaflet. Using these constructs, autologous (n = 3) and allogenic (n = 4) tissue engineered leaflets were implanted in 7 animals. In each animal the right posterior leaflet of the pulmonary valve was resected and replaced with an engineered valve leaflet.

Results

All animals survived the procedure. Postoperative echocardiography demonstrated no evidence of stenosis and trivial pulmonary regurgitation in the autografts and moderate regurgitation in the allogenic valves. Collagen analysis of the constructs showed development of an extracellular matrix. Histologic evaluation of the constructs demonstrated appropriate cellular architecture.

Conclusions

This preliminary experiment showed that a tissue engineered valve leaflet constructed from its cellular components can function in the pulmonary valve position. Tissue engineering of a heart valve leaflet is feasible, and these preliminary studies suggest that autograft tissue will probably be superior to allogenic tissue.

References (10)

VacantiJP et al.
Selective cell transplantation using bioabsorbable artificial polymers as matrices
J Pediatr Surg
(1988)
WattsLK et al.
Establishment of a viable homograft cardiac valve bank: a rapid method of determining homograft viability
Ann Thorac Surg
(1976)
NoishikiY et al.
Acceleration of neointima formation in vas-cular prostheses by transplantation of autologous venous tissue fragments. Application to small-diameter grafts
J Thorac Cardiovasc Surg
(1993)
Breuer CK, Shinoka T, Tanel RE et al. Tissue engineering lamb heart valve leaflets. Biotech Bioeng (in...
SatoM et al.
Relationship between mechanical and hydrodynamic properties of bio-prosthesis produced from canine aortic valve
Artif Organs
(1985)

There are more references available in the full text version of this article.

Cited by (400)

Single-cell RNA sequencing reveals the diversity and biology of valve cells in cardiac valve disease
2023, Journal of Cardiology
From highly aligned extracellular fibrils to the cells, a multilevel ordered hierarchy in valve leaflets is crucial for their biological function. Cardiac valve pathology most frequently involves a disruption in normal structure-function correlations through abnormal and complex interaction of cells, extracellular matrix, and their environment. At present, effective treatment for valve disease is limited and frequently ends with surgical repair or replacement with a mechanical or artificial biological cardiac valve, which comes with insuperable complications for many high-risk patients including aged and pediatric populations. Therefore, there is a critical need to fully appreciate the pathobiology of valve disease in order to develop better, alternative therapies. To date, the majority of studies have focused on delineating valve disease mechanisms at the cellular level. However, the cellular heterogeneity and function is still unclear. In this review, we summarize the body of work on valve cells, with a particular focus on the discoveries about valve cells heterogeneity and functions using single-cell RNA sequencing. We conclude by discussing state-of-the-art strategies for deciphering heterogeneity of these complex cell types, and argue this knowledge could translate into the improved personalized treatment of cardiac valve disease.
Three-Dimensional Printing of Patient-Specific Heart Valves: Separating Facts From Fiction and Myth From Reality
2022, Journal of Cardiothoracic and Vascular Anesthesia
The development of prosthetic heart valves by Dr. Charles Hufnagel in 1952 was a major clinical innovation; however, it was not an ideal solution. Mechanical prosthetic heart valves are rigid, immunogenic, require anticoagulation, do not grow with the patient, and have a finite life.¹ An ideal prosthetic valve should overcome all these limitations. Considering the prevalence of valvular heart disorders, there is considerable interest in the creation of patient-specific heart valves. Following the introduction of three-dimensional (3D) printing in 1986 by Chuck Hill, rapid advances in multimodality 3D imaging and modeling have led to a generation of tangible replicas of patient-specific anatomy. The science of organogenesis has gained importance for a multitude of valid reasons: as an alternate source of organs, for realistic drug testing, as an alternative to animal testing, and for transplants that grow with the patient. What scientists imagined to be seemingly impossible in the past now seems just a step away from becoming a reality. However, due to the disruptive nature of this technology, often there are commercially-motivated claims of originality and overstatement of the scope and applicability of 3D printing. It often is difficult to separate fact from fiction and myth from reality. In this manuscript, the authors have reviewed the historic perspective, status of the basic techniques of organogenesis with specific reference to heart valves, and their potential.
Tissue engineering: Relevance to neonatal congenital heart disease
2022, Seminars in Fetal and Neonatal Medicine
Congenital heart disease (CHD) represents a large clinical burden, representing the most common cause of birth defect-related death in the newborn. The mainstay of treatment for CHD remains palliative surgery using prosthetic vascular grafts and valves. These devices have limited effectiveness in pediatric patients due to thrombosis, infection, limited endothelialization, and a lack of growth potential. Tissue engineering has shown promise in providing new solutions for pediatric CHD patients through the development of tissue engineered vascular grafts, heart patches, and heart valves. In this review, we examine the current surgical treatments for congenital heart disease and the research being conducted to create tissue engineered products for these patients. While much research remains to be done before tissue engineering becomes a mainstay of clinical treatment for CHD patients, developments have been progressing rapidly towards translation of tissue engineering devices to the clinic.
Supramolecular polymer materials bring restorative heart valve therapy to patients
2022, Materials Today
The functional restoration of natural tissues in a variety of cardiovascular applications is the main objective of Endogenous Tissue Restoration (ETR). The recent progress in the development of biocompatible, biodegradable, and tunable biomaterials with unprecedented properties allow the next steps from laboratory studies to clinical studies. The independent control over mechanical properties and biodegradability provided by the combination of covalent and non-covalent bonds makes supramolecular polymers uniquely qualified for ETR. This paper will provide further details on the mechanism of ETR and will provide a perspective on the preclinical and clinical application of supramolecular polymers for ETR. In addition to various reports on chronic studies in large animal models, three world-first clinical studies are reported, demonstrating the potential of supramolecular technology in bringing ETR to patients.
Fibrous heart valve leaflet substrate with native-mimicked morphology
2021, Applied Materials Today
Citation Excerpt :
For heart valve tissue engineering, previous studies have developed tissue constructs by seeding cells on the prepared substrates. These cells were then cultured in a static or dynamic (using a bioreactor) in vitro environment, before in vivo implantation [64,65]. However, substrates similar to ours could not be completely cellularized in vitro, even with a dynamic physiological environment: in fact, cell density would decrease progressively from the surface inward, deep into the substrate [20,28,66].
Tissue-engineered heart valves are a promising alternative solution to prosthetic valves. However, long-term functionalities of tissue-engineered heart valves depend on the ability to mimic the trilayered, oriented structure of native heart valve leaflets. In this study, using electrospinning, we developed trilayered microfibrous leaflet substrates with morphological characteristics similar to native leaflets. The substrates were implanted subcutaneously in rats to study the effect of their trilayered oriented structure on in vivo tissue engineering. The tissue constructs showed a well-defined structure, with a circumferentially oriented layer, a randomly oriented layer and a radially oriented layer. The extracellular matrix, produced during in vivo tissue engineering, consisted of collagen, glycosaminoglycans, and elastin, all major components of native leaflets. Moreover, the anisotropic tensile properties of the constructs were sufficient to bear the valvular physiological load. Finally, the expression of vimentin and α-smooth muscle actin, at the gene and protein level, was detected in the residing cells, revealing their growing state and their transdifferentiation to myofibroblasts. Our data support a critical role for the trilayered structure and anisotropic properties in functional leaflet tissue constructs, and indicate that the leaflet substrates have the potential for the development of valve scaffolds for heart valve replacements.
Biofabrication of poly(L-lactide-co-ε-caprolactone)/silk fibroin scaffold for the application as superb anti-calcification tissue engineered prosthetic valve
2021, Materials Science and Engineering C
In this study, electrospun scaffolds were fabricated by blending poly(l-lactide-co-ε-caprolactone) (PLCL) and silk fibroin (SF) with different ratios, and further the feasibility of electrospun PLCL/SF scaffolds were evaluated for application of tissue engineered heart valve (TEHV). Scanning electron microscopy (SEM) results showed that the surface of PLCL/SF electrospun scaffolds was smooth and uniform while the mechanical properties were appropriate as valve prosthesis. In vitro cytocompatibility evaluation results demonstrated that all of the PLCL/SF electrospun scaffolds were cytocompatible and valvular interstitial cells (VICs) cultured on PLCL/SF scaffolds of 80/20 & 70/30 ratios exhibited the best cytocompatibility. The in vitro osteogenic differentiation of VICs including alkaline phosphatase (ALP) activity and quantitative polymerase chain reaction (qPCR) assays indicated that PLCL/SF scaffolds of 80/20 & 90/10 ratios behaved better anti-calcification ability. In the in vivo calcification evaluation model of rat subdermal implantation, PLCL/SF scaffolds of 80/20 & 90/10 ratios presented better anti-calcification ability, which was consistent with the in vitro results. Moreover, PLCL/SF scaffolds of 80/20 & 70/30 ratios showed significantly enhanced cell infiltration and M2 macrophage with higher CD206+/CD68+ ratio. Collectively, our data demonstrated that electrospun scaffolds with the PLCL/SF ratio of 80/20 hold great potential as TEHV materials.

View all citing articles on Scopus

View full text

Tissue engineering heart valves: Valve leaflet replacement study in a lamb model

Background

Methods

Results

Conclusions

J Pediatr Surg

Ann Thorac Surg

J Thorac Cardiovasc Surg

Relationship between mechanical and hydrodynamic properties of bio-prosthesis produced from canine aortic valve

Artif Organs